Covered recipient · General Payments record
SARITHA ALETI
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$5,612.19
- Reported across 300 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $345.99 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $128.07 | 6 |
| Corcept Therapeutics | $65.37 | 3 |
| Insulet Corporation | $46.14 | 2 |
| DEXCOM, INC. | $20.81 | 1 |
| BETA BIONICS, INC. | $20.00 | 1 |
| Amneal Pharmaceuticals LLC | $19.94 | 1 |
| Amgen Inc. | $19.37 | 1 |
| Tandem Diabetes Care, Inc. | $14.79 | 1 |
| CeQur Corporation | $11.50 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $19.37 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115936556 | CMS |
| Amneal Pharmaceuticals LLC | $19.94 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139178521 | CMS |
| BETA BIONICS, INC. | $20.00 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087883085 | CMS |
| CeQur Corporation | $11.50 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1126844954 | CMS |
| Corcept Therapeutics | $23.45 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117749455 | CMS |
| Corcept Therapeutics | $21.93 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117749515 | CMS |
| Corcept Therapeutics | $19.99 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117749571 | CMS |
| Dexcom, Inc. | $20.81 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153334581 | CMS |
| Insulet Corporation | $19.26 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116794063 | CMS |
| Insulet Corporation | $26.88 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116827616 | CMS |
| Lilly USA, LLC | $25.10 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135408069 | CMS |
| Lilly USA, LLC | $18.05 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135416081 | CMS |
| Lilly USA, LLC | $16.69 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135416083 | CMS |
| Lilly USA, LLC | $13.69 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135418513 | CMS |
| Lilly USA, LLC | $26.61 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135392405 | CMS |
| Lilly USA, LLC | $27.93 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135416085 | CMS |
| Tandem Diabetes Care, Inc. | $14.79 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138748349 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.